Vendor Intelligence Report: Nexaph

Executive summary

Across 253 Finnrick lab tests, Nexaph’s overall pass rate is 60%. The catalog is uneven: GHK-Cu is the clean standout, Tirzepatide and Retatrutide test materially better than the weak end, and CJC-1295 is the clearest avoid signal. Ratings fall under stricter grading, especially where quantity and fill control drive failures.

The investigation also finds a storefront that does not resolve to one clean counterparty. Site materials name Shanghai Nexa Pharma Co, but searched U.S. registries did not produce a matching registration; the operator trail is reconstructed from a site email, Indiana domain data, Florida filings, LinkedIn, reviews and forum records.

Nexaph is bigger than one domain. The report maps same-operator evidence for EZ Peptides, an operator-linked IRON Peptides branch, and non-canonical Nexaph-branded domains that create reseller or clone confusion. A reported Nexaph discount-code signup returning an EZ Peptides coupon email is the kind of backend clue buyers normally never see.

Safety and documentation risks are not abstract. A Tirzepatide T30 batch is documented as failing sterility with Staphylococcus pasteuri, with no recall identified and filtration reportedly advised. COA cloning across sister/reseller brands, handwritten labels, disputed U.S. lyophilization, China-origin synthesis and opaque checkout layers all make vial-to-COA trust the central question.

Inside the full report:

• Appendix A with per-product pass/fail rates, rating trajectories and methodology-divergence charts for all 10 tested products.
• Corporate identity trail from site materials to RDAP, Florida filings, LinkedIn and forum/review records.
• Domain and sister-brand map covering Nexaph, EZ Peptides, IRON Peptides and non-canonical Nexaph domains.
• COA integrity analysis of Janoshik cloning, handwritten labels and batch traceability.
• Tirzepatide T30 sterility review plus supply-chain and checkout analysis of China-origin synthesis, U.S. lyophilization claims, RAI certification and payment descriptors.

Risk assessment

• Aseptic-control and recall-response risk — high: Tirzepatide T30 Christmas batch 2TZ3012242025-20 reportedly failed sterility with Staphylococcus pasteuri; no recall was identified and buyers were reportedly told to filter.
• Product-specific quality risk — high: CJC-1295 (23.02%), Semaglutide (28.95%), Tesamorelin (36.51%), and TB-500 (37.41%) are poor choices from Nexaph in Finnrick’s current record.
• COA and batch-traceability risk — high: Evidence of cloned Janoshik COAs across Nexaph/EZ Peptides/Ameano and reports of handwritten or weak labels undermine vial-to-COA matching.
• Corporate-accountability risk — high: Shanghai Nexa Pharma Co is named on site materials, but no U.S. registration was found; operator identity and brand control are reconstructed from indirect records.
• Manufacturing-claim and supply-chain transparency risk — high: Records support China-origin synthesis while U.S. lyophilization/finishing is disputed and no verified domestic facility address was found.
• Copycat and brand-confusion risk — medium: Non-canonical Nexaph-branded domains and reseller-like sites exist, and no authoritative reseller list or anti-counterfeit controls were identified.
• Payment and buyer-recourse risk — medium: Opaque billing descriptors, crypto incentives, ACH payable to an unverified entity name, RAI certification costs, and chargeback-ban allegations reduce recourse.
• Regulatory-enforcement disruption risk — medium: Grey-market GLP-1 peptide enforcement, a CBP peptide seizure trend, and the reported Wuhan Marco raid create shipment and continuity risk.